US4460685A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of enhancing the production of human γ Interferon
Assignee: New York University
•
Filing: 1981-04-17
•
Granted: 1984-07-17
•
Expires: 2001-04-17
Abstract
Abstract A method for stimulating the production of human IFN- gamma in a culture of cells is disclosed. In this method, an effective amount of a diterpene compound is added to a culture of IFN- gamma producing cells.
Inventors
- 👤 Jan T. Vilcek
- 👤 Yum K. Yip
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 06:12
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/555; C07K14/57; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/811
Claims Analysis
Total Claims: 39
Claim 1
Independent Claim
37 words
In the production of human IFN-γ from IFN-γ-producing leukocyte cells: the improvement of stimulating IFN-γ production by contacting said cells with an effective IFN-γ-production-stimulating amount of at least one IFN-γ stimulating diterpene compound and thereafter isolating IFN-γ.
Claim 2
Dependent Claim
37 words
In the production of human IFN-γ from IFN-γ-producing leukocyte cells: the improvement of stimulating IFN-γ production by contacting said cells with an effective IFN-γ-production-stimulating amount of at least one IFN-γ stimulating diterpene compound and thereafter isolating IFN-γ.
Claim 3
Dependent Claim
13 words
The improvement of claim 1 wherein said diterpene compound comprises a phorbol ester.
Claim 4
Dependent Claim
11 words
The improvement of claim 2 wherein said phorbol ester comprises 12-0-tetradecanoylphorbol-13-acetate.
Claim 5
Dependent Claim
11 words
The improvement of claim 1 wherein said diterpene compound comprises mezerein.
Claim 6
Independent Claim
72 words
A method of producing human IFN-γ, comprising: (a) forming a cell culture of human IFN-γ-producing leukocyte cells in a suitable cell culture medium; (b) introducing an IFN-γ inducing material into said cell culture in an effective inducing amount; (c) introducing an IFN-γ stimulating diterpene compound into said culture in an effective IFN-γ-production-stimulating amount; (d) maintaining said cell culture under conditions conducive to IFN-γ production; and (e) isolating IFN-γ from said cell culture.
Claim 7
Independent Claim
72 words
A method of producing human IFN-γ, comprising: (a) forming a cell culture of human IFN-γ-producing leukocyte cells in a suitable cell culture medium; (b) introducing an IFN-γ inducing material into said cell culture in an effective inducing amount; (c) introducing an IFN-γ stimulating diterpene compound into said culture in an effective IFN-γ-production-stimulating amount; (d) maintaining said cell culture under conditions conducive to IFN-γ production; and (e) isolating IFN-γ from said cell culture.
Claim 8
Dependent Claim
24 words
The method of claim 5 additionally including the step of introducing a human IFN-γ inducer into said cell culture in an effective IFN-γ-inducing amount.
Claim 9
Dependent Claim
12 words
A method of claim 6 wherein said IFN-γ inducer comprises a mitogen.
Claim 10
Dependent Claim
13 words
A method of claim 6 wherein said IFN-γ inducer comprises a plant lectin.
Claim 11
Independent Claim
11 words
A method of clam 8 wherein said plant lectin comprises phytohemagglutinin.
Claim 12
Independent Claim
11 words
A method of clam 8 wherein said plant lectin comprises phytohemagglutinin.
Claim 13
Dependent Claim
12 words
A method of claim 8 wherein said patent lectin comprises concanavalin A.
Claim 14
Dependent Claim
13 words
A method of claim 6 wherein said IFN-γ inducer comprises a bacterial toxin.
Claim 15
Dependent Claim
13 words
A method of claim 11 wherein said bacterial toxin comprises staphylococcal enterotoxin A.
Claim 16
Dependent Claim
12 words
A method of claim 6 wherein said IFN-γ inducer comprises an enzyme.
Claim 17
Dependent Claim
11 words
A method of claim 13 wherein said enzyme comprises galactose oxidase.
Claim 18
Dependent Claim
13 words
A method of claim 6 wherein said IFN-γ inducer comprises Staphylococcal protein A.
Claim 19
Dependent Claim
12 words
A method of claim 6 wherein said IFN-γ inducer comprises antilymphocyte antiserum.
Claim 20
Dependent Claim
13 words
A method of claim 16 wherein said antilymphocyte antiserum comprises a monoclonal antibody.
Claim 21
Dependent Claim
11 words
A method of claim 17 wherein said monoclonal antibody comprises OKT3.
Claim 22
Independent Claim
16 words
A method of claims 5, 8, 10 or 16 wherein said IFN-γ stimulating compound comprises 12-0-tetradecanoylphorbol-13-acetate.
Claim 23
Independent Claim
16 words
A method of claims 5, 8, 10 or 16 wherein said IFN-γ stimulating compound comprises mezerein.
Claim 24
Dependent Claim
65 words
A method of claim 5 wherein said IFN-γ stimulating compound comprises a compound represented by the structural formula ##STR3## wherein R 1 , R 2 , R 3 and R 4 are individually selected from hydrogen, alkyl, alkoxy, carboxy, keto, aryl and alkaryl groups, and at least one of R 1 and R 2 forms an ester functionality at the 12 or 13 ring position.
Claim 25
Dependent Claim
27 words
A method of claim 21 wherein R 1 =C 13 H 27 CO--, R 2 =CH 3 CO--, R 3 =H or OH, and R 4 =H.
Claim 26
Dependent Claim
18 words
A method of claim 5 wherein said IFN-γ stimulating comprises a compound represented by the structural formula ##STR4##
Claim 27
Independent Claim
22 words
A method of claims 5, 21 or 23 wherein said IFN-γ producing cells comprise unprocessed cytopheresis residues or unprocessed buffy coat cells.
Claim 28
Dependent Claim
59 words
In a method for producing mRNA for IFN-γ in a culture of IFN-γ producing white blood cells including contacting said cells with an IFN-γ inducer: the improvement of contacting said cells with an effective amount of an IFN-γ-stimulating diterpene compound to thereby raise the level of mRNA for IFN-γ in said culture and thereafter isolating said mRNA for IFN-γ.
Claim 29
Dependent Claim
59 words
In a method for producing mRNA for IFN-γ in a culture of IFN-γ producing white blood cells including contacting said cells with an IFN-γ inducer: the improvement of contacting said cells with an effective amount of an IFN-γ-stimulating diterpene compound to thereby raise the level of mRNA for IFN-γ in said culture and thereafter isolating said mRNA for IFN-γ.
Claim 30
Independent Claim
74 words
A method of producing mRNA for IFN-γ, comprising: (a) forming a culture of IFN-γ producing leukocyte cells; (b) adding an IFN-stimulating diterpene compound to said culture in an effective amount for enhancing cellular elaboration of IFN-γ; (c) optionally adding an IFN-γ inducer to said culture; (d) incubating said cells under conditions conducive to IFN-γ production; (e) extracting RNA from said culture; (f) purifying said RNA to produce a fraction enriched in mRNA for IFN-γ.
Claim 31
Independent Claim
74 words
A method of producing mRNA for IFN-γ, comprising: (a) forming a culture of IFN-γ producing leukocyte cells; (b) adding an IFN-stimulating diterpene compound to said culture in an effective amount for enhancing cellular elaboration of IFN-γ; (c) optionally adding an IFN-γ inducer to said culture; (d) incubating said cells under conditions conducive to IFN-γ production; (e) extracting RNA from said culture; (f) purifying said RNA to produce a fraction enriched in mRNA for IFN-γ.
Claim 32
Dependent Claim
13 words
A method of claim 26 wherein said diterpene compound comprises a phorbol ester.
Claim 33
Dependent Claim
11 words
A method of claim 27 wherein said phorbol ester comprises 12-0-tetradecanoylphorbol-13-acetate.
Claim 34
Dependent Claim
11 words
A method of claim 26 wherein said diterpene compound comprises mezerein.
Claim 35
Independent Claim
52 words
A method of producing IFN-γ, comprising: (a) forming a culture of IFN-γ-producing white blood cells; (b) introducing an effective IFN-γ-inducing amount of an IFN-γ inducer and an effective IFN-γ-stimulating amount of mezerein into said culture; (c) maintaining said culture under conditions conducive to the production of IFN-γ; and (d) isolating human IFN-γ.
Claim 36
Independent Claim
52 words
A method of producing IFN-γ, comprising: (a) forming a culture of IFN-γ-producing white blood cells; (b) introducing an effective IFN-γ-inducing amount of an IFN-γ inducer and an effective IFN-γ-stimulating amount of mezerein into said culture; (c) maintaining said culture under conditions conducive to the production of IFN-γ; and (d) isolating human IFN-γ.
Claim 37
Independent Claim
54 words
A method of producing human IFN-γ, comprising: (a) forming a culture of IFN-γ-producing white blood cells; (b) introducing an effective IFN-γ-inducing amount of an IFN-γ inducer and an effective IFN-γ-stimulating amount of phorbol ester into said culture; (c) maintaining said culture under conditions conducive to the production of IFN-γ; and, (d) isolating human IFN-γ.
Claim 38
Independent Claim
54 words
A method of producing human IFN-γ, comprising: (a) forming a culture of IFN-γ-producing white blood cells; (b) introducing an effective IFN-γ-inducing amount of an IFN-γ inducer and an effective IFN-γ-stimulating amount of phorbol ester into said culture; (c) maintaining said culture under conditions conducive to the production of IFN-γ; and, (d) isolating human IFN-γ.
Claim 39
Dependent Claim
11 words
A method of claim 31 wherein said phorbol ester comprises 12-O-tetradecanoylphorbol-13-acetate.
References Cited (Backward Citations)
US4262090A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-07-17 | 1988-01-16 | 1988-07-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-07-17 | 1992-01-16 | 1992-07-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-07-17 | 1996-01-16 | 1996-07-17 | $7700.00 | Window Closed / Lapsed |